medigraphic.com
ISSN 3061-8142 (Electronic)

2026, Number S1

<< Back Next >>

Rev Mex Anest 2026; 49 (S1)

Pheochromocytoma: preoperative optimization and hemodynamic stabilization during tumor management

Domínguez-Cherit JG

Language: Spanish
References: 40
Page: 277-280
PDF size: 849.85 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, GrebeSK, Murad MH, et al. Pheochromocytoma and paraganglioma: anEndocrine Society clinical practice guideline. J Clin Endocrinol Metab.

  2. 2014;99:1915-1942.2. Nolting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, KroissM, et al. Personalized management of pheochromocytoma andparaganglioma. Endocr Rev. 2022;43:199-239.

  3. Naranjo J, Dodd S, Martin YN. Perioperative management ofpheochromocytoma. J Cardiothorac Vasc Anesth. 2017;31:1427-1439.

  4. Lord MS, Augoustides JG. Perioperative management ofpheochromocytoma: focus on magnesium, clevidipine, and vasopressin.J Cardiothorac Vasc Anesth. 2012;26:526-531.

  5. Lindstrom EJ, Attaallah AF. Novel use of clevidipine for intraoperativeblood pressure management in patients with pheochromocytoma. AANAJ. 2016;84:343-347.

  6. Luis-García C, Arbonés-Aran E, Teixell-Aleu C, Lorente-Poch L, Trillo-Urrutia L. Clevidipine for hypertension treatment in pheochromocytomasurgery. Rev Esp Anestesiol Reanim (Engl Ed). 2018;65:225-228.

  7. Buonanno A, Bruzzese D, Battagliese M, et al. Clevidipine for themanagement of hypertension in the perioperative settings: a systematicreview. Front Med (Lausanne). 2025;12:1562681.

  8. Ma M, Zhang X, Yu X, Ma L. Perioperative management and outcomeof catecholamine-induced Takotsubo and dilated cardiomyopathy inpheochromocytoma and paraganglioma. J Cardiothorac Vasc Anesth.2025 May;39:1275-1281.

  9. Augoustides JG, Abrams M, Berkowitz D, Fraker D. Vasopressin forhemodynamic rescue in catecholamine-resistant vasoplegic shockafter resection of massive pheochromocytoma. Anesthesiology.2004;101:1022-1024.

  10. Weingarten TN, Cata JP, O’Hara JF, Prybilla DJ, Pike TL, Thompson GB,et al. Comparison of two preoperative medical management strategiesfor laparoscopic resection of pheochromocytoma. Urology. 2010;76:508.e6–508.e11.

  11. Pacak K. Preoperative management of the pheochromocytoma patient.J Clin Endocrinol Metab. 2007;92:4069-4079.

  12. Ramakrishna H. Pheochromocytoma resection: current concepts inanesthetic management. J Anaesthesiol Clin Pharmacol. 2015;31:317-323.

  13. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, BeckmanJA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperativecardiovascular evaluation and management of patients undergoingnoncardíac surgery. Circulation. 2014;130:e278-e333.

  14. Araujo-Castro M, García-Centeno R, López-García MC, et al.Multidisciplinary practice guidelines for the diagnosis and treatment ofpheochromocytomas and paragangliomas. Eur J Intern Med. 2021;91:98-117.

  15. Holt NF, Silverman DG, Prasad R, et al. Pheochromocytomas andparagangliomas: considerations for the anesthesiologist. AnesthesiolClin. 2020;38:95-113.

  16. Jogini V, Bhargavan Nair B, Paluvoi N, et al. Preoperative preparationand intraoperative management of pheochromocytoma/paraganglioma.Ann Card Anaesth. 2021;24:153-160.

  17. Lentschener C, Gaujoux S, Tesniere A, Dousset B. Point of controversy:perioperative care of patients undergoing pheochromocytoma removal.Eur J Endocrinol. 2011;165:365-373.

  18. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and futureprospects. Endocr Rev. 2003;24:539-553.

  19. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma.Lancet. 2005;366:665-675.

  20. Kline JP. Use of clevidipine for intraoperative hypertension caused by anundiagnosed pheochromocytoma: a case report. AANA J. 2010;78:288-290.

  21. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, GrebeSK, Murad MH, et al. Pheochromocytoma and paraganglioma: anEndocrine Society clinical practice guideline. J Clin Endocrinol Metab.

  22. 2014;99:1915-1942.2. Nolting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, KroissM, et al. Personalized management of pheochromocytoma andparaganglioma. Endocr Rev. 2022;43:199-239.

  23. Naranjo J, Dodd S, Martin YN. Perioperative management ofpheochromocytoma. J Cardiothorac Vasc Anesth. 2017;31:1427-1439.

  24. Lord MS, Augoustides JG. Perioperative management ofpheochromocytoma: focus on magnesium, clevidipine, and vasopressin.J Cardiothorac Vasc Anesth. 2012;26:526-531.

  25. Lindstrom EJ, Attaallah AF. Novel use of clevidipine for intraoperativeblood pressure management in patients with pheochromocytoma. AANAJ. 2016;84:343-347.

  26. Luis-García C, Arbonés-Aran E, Teixell-Aleu C, Lorente-Poch L, Trillo-Urrutia L. Clevidipine for hypertension treatment in pheochromocytomasurgery. Rev Esp Anestesiol Reanim (Engl Ed). 2018;65:225-228.

  27. Buonanno A, Bruzzese D, Battagliese M, et al. Clevidipine for themanagement of hypertension in the perioperative settings: a systematicreview. Front Med (Lausanne). 2025;12:1562681.

  28. Ma M, Zhang X, Yu X, Ma L. Perioperative management and outcomeof catecholamine-induced Takotsubo and dilated cardiomyopathy inpheochromocytoma and paraganglioma. J Cardiothorac Vasc Anesth.2025 May;39:1275-1281.

  29. Augoustides JG, Abrams M, Berkowitz D, Fraker D. Vasopressin forhemodynamic rescue in catecholamine-resistant vasoplegic shockafter resection of massive pheochromocytoma. Anesthesiology.2004;101:1022-1024.

  30. Weingarten TN, Cata JP, O’Hara JF, Prybilla DJ, Pike TL, Thompson GB,et al. Comparison of two preoperative medical management strategiesfor laparoscopic resection of pheochromocytoma. Urology. 2010;76:508.e6–508.e11.

  31. Pacak K. Preoperative management of the pheochromocytoma patient.J Clin Endocrinol Metab. 2007;92:4069-4079.

  32. Ramakrishna H. Pheochromocytoma resection: current concepts inanesthetic management. J Anaesthesiol Clin Pharmacol. 2015;31:317-323.

  33. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, BeckmanJA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperativecardiovascular evaluation and management of patients undergoingnoncardíac surgery. Circulation. 2014;130:e278-e333.

  34. Araujo-Castro M, García-Centeno R, López-García MC, et al.Multidisciplinary practice guidelines for the diagnosis and treatment ofpheochromocytomas and paragangliomas. Eur J Intern Med. 2021;91:98-117.

  35. Holt NF, Silverman DG, Prasad R, et al. Pheochromocytomas andparagangliomas: considerations for the anesthesiologist. AnesthesiolClin. 2020;38:95-113.

  36. Jogini V, Bhargavan Nair B, Paluvoi N, et al. Preoperative preparationand intraoperative management of pheochromocytoma/paraganglioma.Ann Card Anaesth. 2021;24:153-160.

  37. Lentschener C, Gaujoux S, Tesniere A, Dousset B. Point of controversy:perioperative care of patients undergoing pheochromocytoma removal.Eur J Endocrinol. 2011;165:365-373.

  38. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and futureprospects. Endocr Rev. 2003;24:539-553.

  39. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma.Lancet. 2005;366:665-675.

  40. Kline JP. Use of clevidipine for intraoperative hypertension caused by anundiagnosed pheochromocytoma: a case report. AANA J. 2010;78:288-290.




2020     |     www.medigraphic.com